Enzyme replacement therapy in orphan and ultra-orphan diseases
BackgroundFabry-Anderson disease is an x-linked deficiency of lysosomal α-galactosidase A (GALA), resulting in chronic renal failure, cardiac arrhythmia, hypertrophy, valvular disease, pain (acro-paraesthesiae) and stroke, together with premature mortality. The disease has a significant impact on qu...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2007
|
| In: |
PharmacoEconomics
Year: 2007, Jahrgang: 25, Heft: 3, Pages: 201-208 |
| ISSN: | 1179-2027 |
| DOI: | 10.2165/00019053-200725030-00003 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.2165/00019053-200725030-00003
|
| Verfasserangaben: | David F. Moore, Markus Ries, Evelyn L. Forget and Raphael Schiffmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1665724544 | ||
| 003 | DE-627 | ||
| 005 | 20230427160224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190515s2007 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00019053-200725030-00003 |2 doi | |
| 035 | |a (DE-627)1665724544 | ||
| 035 | |a (DE-599)KXP1665724544 | ||
| 035 | |a (OCoLC)1341224543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Moore, David F. |e VerfasserIn |0 (DE-588)1185726535 |0 (DE-627)1665088176 |4 aut | |
| 245 | 1 | 0 | |a Enzyme replacement therapy in orphan and ultra-orphan diseases |c David F. Moore, Markus Ries, Evelyn L. Forget and Raphael Schiffmann |
| 264 | 1 | |c 2007 | |
| 264 | 4 | |c 22 September 2012 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First online: 22 September 2012 | ||
| 500 | |a Gesehen am 15.05.2019 | ||
| 520 | |a BackgroundFabry-Anderson disease is an x-linked deficiency of lysosomal α-galactosidase A (GALA), resulting in chronic renal failure, cardiac arrhythmia, hypertrophy, valvular disease, pain (acro-paraesthesiae) and stroke, together with premature mortality. The disease has a significant impact on quality of life (QOL), as illustrated by studies using the EQ-5D. A specific treatment is available for Fabry-Anderson disease consisting of intravenous enzyme replacement therapy (ERT) of the deficient enzyme. The variable clinical efficacy and cost of ERT has resulted in reluctance by some health providers to approve it.MethodsWe use the limited QOL data available in the Fabry-Anderson disease literature on ERT to derive standard economic metrics. These were derived by bootstrap estimates of the incremental net benefit (INB) statistics together with a cost-effectiveness acceptability curve relating the willingness to pay to the probability that the INB was >0. The estimates were further developed by adoption of a supplementary Bayesian approach utilising a sceptical and enthusiastic prior of the INB of ERT in Fabry-Anderson disease.ResultsERT for Fabry-Anderson disease is not economically viable by standard health programme evaluation metrics. Based on current ERT costs (year 2005 values), derivation of the INB distribution, and a Bayesian analysis using an enthusiastic and sceptical prior of the INB, an upper ($US350 000 over 1 year) and lower ($US175 000 over 1 year) economic cost, respectively, of ERT was derived.ConclusionThe cost of ERT will always result in a net deficit to society under current costing and ERT efficacy as determined by the QALY metric. The rules of fair cooperation should govern decision making both for ERT in Fabry-Anderson disease and for funding therapeutic advances in other rare diseases belonging to the orphan and ultra-orphan categories. | ||
| 650 | 4 | |a Agalsidase Beta | |
| 650 | 4 | |a Corneal Dystrophy | |
| 650 | 4 | |a Enzyme Replacement Therapy | |
| 650 | 4 | |a Fabry Outcome Survey | |
| 650 | 4 | |a Orphan Drug Legislation | |
| 700 | 1 | |a Ries, Markus |d 1971- |e VerfasserIn |0 (DE-588)136385338 |0 (DE-627)582068479 |0 (DE-576)300993358 |4 aut | |
| 700 | 1 | |a Forget, Evelyn L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schiffmann, Raphael |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics |d Berlin [u.a.] : Springer, 1992 |g 25(2007), 3, Seite 201-208 |h Online-Ressource |w (DE-627)327645717 |w (DE-600)2043876-X |w (DE-576)273880853 |x 1179-2027 |7 nnas |a Enzyme replacement therapy in orphan and ultra-orphan diseases |
| 773 | 1 | 8 | |g volume:25 |g year:2007 |g number:3 |g pages:201-208 |g extent:8 |a Enzyme replacement therapy in orphan and ultra-orphan diseases |
| 856 | 4 | 0 | |u https://doi.org/10.2165/00019053-200725030-00003 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190515 | ||
| 993 | |a Article | ||
| 994 | |a 2007 | ||
| 998 | |g 136385338 |a Ries, Markus |m 136385338:Ries, Markus |p 2 | ||
| 999 | |a KXP-PPN1665724544 |e 3476075346 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["First online: 22 September 2012","Gesehen am 15.05.2019"],"recId":"1665724544","id":{"doi":["10.2165/00019053-200725030-00003"],"eki":["1665724544"]},"title":[{"title_sort":"Enzyme replacement therapy in orphan and ultra-orphan diseases","title":"Enzyme replacement therapy in orphan and ultra-orphan diseases"}],"relHost":[{"id":{"zdb":["2043876-X"],"eki":["327645717"],"issn":["1179-2027"]},"title":[{"subtitle":"economic evaluations of drug therapy in disease management","title":"PharmacoEconomics","title_sort":"PharmacoEconomics"}],"disp":"Enzyme replacement therapy in orphan and ultra-orphan diseasesPharmacoEconomics","note":["Gesehen am 15.05.14"],"part":{"text":"25(2007), 3, Seite 201-208","volume":"25","issue":"3","year":"2007","extent":"8","pages":"201-208"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"origin":[{"publisher":"Springer ; Adis Intern.","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisherPlace":"Berlin [u.a.] ; Auckland"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1992 -"],"recId":"327645717"}],"person":[{"roleDisplay":"VerfasserIn","family":"Moore","given":"David F.","display":"Moore, David F.","role":"aut"},{"family":"Ries","roleDisplay":"VerfasserIn","role":"aut","display":"Ries, Markus","given":"Markus"},{"roleDisplay":"VerfasserIn","family":"Forget","given":"Evelyn L.","role":"aut","display":"Forget, Evelyn L."},{"given":"Raphael","role":"aut","display":"Schiffmann, Raphael","roleDisplay":"VerfasserIn","family":"Schiffmann"}],"name":{"displayForm":["David F. Moore, Markus Ries, Evelyn L. Forget and Raphael Schiffmann"]},"physDesc":[{"extent":"8 S."}],"origin":[{"dateIssuedKey":"2007","dateIssuedDisp":"2007"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"]} | ||
| SRT | |a MOOREDAVIDENZYMEREPL2007 | ||